Danish Pharmacovigilance Update, March 2017

18 April 2017

In this issue

  • The European Pharmacovigilance Risk Assessment Committee, PRAC, recommends regulatory measures – including suspension of the marketing authorisation for some gadolinium-containing contrast agents
  • The DKMA seeks more knowledge about the use of quetiapine in children and adolescents
  • Childhood vaccinations and reported suspected adverse reactions in Q4 of 2016
  • EU's list of recommendations on safety signals
  • Most recent Direct Healthcare Professional Communications (DHPCs)

Link

Danish Pharmocovigilance Update, March 2017